Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 1 of 45 PageID #: 9131
`Case 1:17-cv-00868—CFC-SRF Document 229-1 Filed 06/30/20 Page 1 of 45 PageID #: 9131
`
`EXHIBIT “(cid:36)”
`
`EXHIBIT “A”
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 2 of 45 PageID #: 9132
`
`
`
`
`
`
`
`
`Financial
`Data
`
`
`
`Technical
`Documents
`
`
`Formulation/
`Ingredient
`list
`
`
`Product Identified by Plaintiffs in D.I. 88 Ex. A
`
`Current Status of Production
`
`(cid:120) Lancôme Absolue Revitalizing Eye Cream
`(2013 and later)
`
`(cid:120) La Roche-Posay Redermic R (2011-2012)
`(cid:120) Vichy LiftActiv Retinol Anti-Wrinkle Cream (2011-12)
`(cid:120) Vichy LiftActiv Retinol HA Night (2011-2012)
`(cid:120) Vichy LiftActiv Retinol HA Eyes (2011-2012)
`(cid:120) Vichy Liftactiv Supreme Eyes (2011-2012)
`
`(cid:120) Lancôme Absolue Revitalizing Eye Cream
`
`(cid:120) Giorgio Armani Crema Nera Extrema High Recovery
`Elixir
`(cid:120) Giorgio Armani Regenessence 3.R High Lift Eyes
`(cid:120) L’Oréal Paris True Match Lumi Cushion Foundation
`(cid:120) Vichy Neovadiol Eye & Lip Contours
`(cid:120) Lancôme Absolue Revitalizing Brightening Soft Cream
`(cid:120) Lancôme Absolue Rich Cream
`(cid:120) Lancôme Absolue Sublime Oleo-Serum
`(cid:120) Lancôme Renergie Lift Multi-Glow Rosy Skin Tone
`Reviving Cream
`
`L’Oréal USA produced records
`showing that this product was not
`launched until 2019. (LOUSA6014-
`19; 6029-34.)
`L’Oréal USA has produced financial
`records for these products from 2013
`through 2018. L’Oréal USA has
`informed Plaintiffs that its financial
`database for these products does not go
`back earlier than 2013. L’Oréal USA
`is working to obtain the 2011 and 2012
`data, if it exists, from other sources.
`L’Oréal USA produced records
`showing that this product was not
`launched until 2019. (LOUSA6014-
`19; 6029-34.)
`Unable to locate.
`
`L’Oréal USA produced records
`showing that these products were not
`launched until 2019. (LOUSA3056;
`LOUSA6014-19; LOUSA6029-34.)
`
`
`
`1
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 3 of 45 PageID #: 9133
`
`
`
`
`
`
`
`
`
`
`
`Formulation/
`Ingredient
`list
`
`
`
`
`
`
`Product
`Packaging
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Product Identified by Plaintiffs in D.I. 88 Ex. A
`
`Current Status of Production
`
`(cid:120) Giorgio Armani Crema Nera Light Reviving Eye Cream
`(cid:120) Giorgio Armani Crema Nera Supreme Recovery Balm
`(cid:120) Giorgio Armani Designer Lift Smoothing Firming
`Foundation SPF 20
`(cid:120) Kiehl’s BB Cream
`
`(cid:120) Lancôme Advanced Genifique Sensitive
`(cid:120) Lancôme Absolue Ultimate Elixir-Concentrate
`(cid:120) Lancôme Absolue Ultimate Night BX Serum
`(cid:120) Lancôme Renergie Eclat Multi-Lift
`(cid:120) Lancôme Renergie Lift Multi-Action Day Cream
`(cid:120) Lancôme Renergie Lift Multi-Action Light Cream
`(cid:120) Lancôme Renergie Night
`(cid:120) Lancôme Renergie Eye Anti-Wrinkle and Firming Eye
`Cream
`(cid:120) Lancôme Teint Visionnaire
`(cid:120) Vichy Liftactiv Supreme Eyes
`(cid:120) Vichy Liftactiv Supreme Serum 10 Eyes & Lashes
`(cid:120) Yves Saint Laurent Or Rouge Crème Riche
`(cid:120) Yves Saint Laurent Or Rouge Serum
`(cid:120) Yves Saint Laurent Top Secrets CC Cream Color
`Correcting Primer
`(cid:120) Lancôme Advanced Genifique Sensitive
`
`(cid:120) Lancôme Visionnaire Advanced Skin Corrector
`
`(cid:120) Lancôme Advanced Genifique Hydrogel Melting Sheet
`Mask
`(cid:120) Lancôme Advanced Genifique Yeux Light-Pearl
`Hydrogel Melting Eye Mask
`(cid:120) L’Oréal Paris RevitaLift Triple Power SPF 30 Day
`Lotion
`(cid:120) L’Oréal Paris Youth Code Day Lotion SPF 30
`(cid:120) L’Oréal Paris Age Perfect Rosy Tone SPF 30 Sunscreen
`Face Moisturizer
`(cid:120) L’Oréal Paris RevitaLift Volume Filler Night Cream
`
`2
`
`Unable to locate.
`
`Produced on December 20, 2019 at
`LOUSA2872-73
`Produced on December 6, 2019 at
`LOUSA1998 and on December 20,
`2019 at LOUSA2870. L’Oréal USA
`also explained to Plaintiffs that this
`product was the same as Visionnaire
`Serum, which is listed separately on
`their accused products list. Plaintiffs
`acknowledged this in an email dated
`January 23, 2020.
`L’Oréal USA produced records
`showing that these products were not
`launched until 2019. (LOUSA6014-
`19; 6029-34.)
`Produced on Feb. 12, 2020, at
`LOUSA6658-6664.
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 4 of 45 PageID #: 9134
`
`
`
`
`
`
`
`
`
`
`
`
`Product
`Packaging
`
`
`
`
`
`Additional
`Marketing
`Materials
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Product Identified by Plaintiffs in D.I. 88 Ex. A
`
`Current Status of Production
`
`(cid:120) L’Oréal Paris RevitaLift Triple Power Intensive Anti-
`Aging Day Cream Moisturizer Fragrance Free
`(cid:120) L’Oréal Paris Visible Lift Radiance Booster
`(cid:120) Biotherm Blue Therapy Eye
`(cid:120) Biotherm Blue Therapy Night
`(cid:120) Biotherm Blue Therapy Serum in Oil
`(cid:120) Biotherm Blue Therapy Eye-Opening Serum
`(cid:120) Biotherm Blue Therapy Accelerated Serum
`
`(cid:120) Decleor Orexcellence Energy Concentrate Youth Cream
`(cid:120) Decleor Orexcellence Energy Concentrate Youth Mask
`(cid:120) Decleor Orexcellence Energy Concentrate Youth Eye
`Care
`(cid:120) Lancôme Teint Visionnaire
`
`(cid:120) Vichy LiftActiv Retinol HA Night
`(cid:120) Vichy LiftActiv Retinol HA Eyes
`(cid:120) Vichy Neovadiol Compensating Complex
`(cid:120) Vichy ProEven Daily Dark Spot Serum Corrector
`
`(cid:120) Garnier Ultra-Lift Anti-Wrinkle Night Cream
`
`(cid:120) Lancôme Absolue Premium BX Eye
`
`(cid:120) Lancôme Absolue Premium BX Lotion SPF 15
`
`(cid:120) Lancôme High Resolution Eye Refill 3X
`
`3
`
`As L’Oréal USA informed Plaintiffs
`during discovery, Biotherm is not a
`L’Oréal USA brand. L’Oréal USA has
`requested responsive documents from
`Canada so that Plaintiffs do not need to
`pursue through the Hague.
`As L’Oréal USA informed Plaintiffs
`during discovery, Decleor is not a
`L’Oréal USA brand, but is working to
`obtain responsive documents.
`This product is not a skincare product
`and has been discontinued. L’Oréal
`USA is working to obtain responsive
`documents.
`Unable to locate. L’Oréal USA has
`requested responsive documents from
`L’Oréal SA in France so that Plaintiffs
`do not need to pursue through the
`Hague.
`Produced on Jan. 31, 2020 at
`LOUSA4264-76.
`
`Produced on Dec. 20, 2019 at
`LOUSA2986-87, on Feb. 7, 2020 at
`LOUSA5012-5103; LOUSA5280-
`5347; LOUSA5441-5558 and
`LOUSA5559-5738 and on Feb. 10,
`2020 at LOUSA6434-6581 and
`LOUSA6582-6645.
`Produced on Feb. 7, 2020 at
`LOUSA4831-5011; LOUSA5012-
`5103 and LOUSA5559-5738 and on
`Feb. 10, 2010 at LOUSA6308-6341.
`
`Produced on Feb. 7, 2020 at
`LOUSA4661-4830 and LOUSA5280-
`5347 and on Feb. 10, 2020 at
`LOUSA6342-6387; LOUSA6434-
`6581 and LOUSA6582.
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 5 of 45 PageID #: 9135
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Additional
`Marketing
`Materials
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Product Identified by Plaintiffs in D.I. 88 Ex. A
`
`Current Status of Production
`
`(cid:120) Lancôme High Resolution Night Refill 3X
`
`(cid:120) Lancôme Renergie Day Cream Double Performance
`Treatment Anti-Wrinkle-Firming
`(cid:120) Lancôme Renergie Lift Multi-Action Light Cream
`
`(cid:120) Lancôme Renergie Night
`
`(cid:120) Lancôme Absolue Revitalizing Oleo Serum
`(cid:120) Lancôme Absolue Rich Cream
`
`(cid:120) Lancôme Renergie Yeux Multi-Glow Glow Awakening
`and Reinforcing Eye Cream
`(cid:120) Lancôme Advanced Genifique Yeux Light-Pearl
`Hydrogel Melting Eye Mask
`(cid:120) Lancôme Renergie Lift Multi-Glow Rosy Skin Tone
`Reviving Cream
`(cid:120) Yves Saint Laurent Top Secrets Instant Matte Pore
`Refiner
`(cid:120) Biotherm Blue Therapy Eye
`(cid:120) Biotherm Blue Therapy Night
`(cid:120) Biotherm Blue Therapy Serum in Oil
`(cid:120) Biotherm Blue Therapy Eye-Opening Serum
`(cid:120) Biotherm Blue Therapy Accelerated Serum
`(cid:120) Decleor Orexcellence Energy Concentrate Youth Cream
`(cid:120) Decleor Orexcellence Energy Concentrate Youth Mask
`(cid:120) Decleor Orexcellence Energy Concentrate Youth Eye
`Care
`
`(cid:120) Lancôme Renergie Lift Multi-Action Firming Mask
`
`4
`
`Produced on Feb. 7, 2020 at
`LOUSA4661-4830 and LOUSA5280-
`5347 and on Feb. 10, 2020 at
`LOUSA6434-6581.
`Produced on Feb. 7, 2020 at
`LOUSA5242-5279.
`Produced on Feb. 7, 2020 at
`LOUSA4831-5011; LOUSA5012-
`5103; LOUSA5559-5738 and
`LOUSA5739-5864.
`
`Produced on Feb. 7, 2020 at
`LOUSA5242-5279 and LOUSA5280-
`5347.
`
`L’Oréal USA produced records
`showing that these products were not
`launched until 2019. (LOUSA6014-
`19; 6029-34.) L’Oréal USA also
`produced marketing materials for these
`products on Feb. 10, 2020 at
`LOUSA6295-6307.
`L’Oréal USA produced records
`showing that these products were not
`launched until 2019. (LOUSA3056;
`LOUSA3059; LOUSA6014-19; 6023-
`24; 6029-34.)
`
`As L’Oréal USA informed Plaintiffs
`during discovery, Biotherm is not a
`L’Oréal USA brand. L’Oréal USA has
`requested responsive documents from
`Canada so that Plaintiffs do not need to
`pursue through the Hague.
`As L’Oréal USA informed Plaintiffs
`during discovery, Decleor is not a
`L’Oréal USA brand, but L’Oréal USA
`is working to obtain responsive
`documents.
`Unable to locate. L’Oréal USA has
`requested responsive documents from
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 6 of 45 PageID #: 9136
`
`
`
`
`
`
`
`
`
`
`Additional
`Marketing
`Materials
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Product Identified by Plaintiffs in D.I. 88 Ex. A
`
`Current Status of Production
`
`L’Oréal SA in France so that Plaintiffs
`do not need to pursue through the
`Hague.
`As L’Oréal USA informed Plaintiffs
`during the parties’ meet and confer on
`January 30, 2020, no responsive
`documents exist.
`
`Unable to locate.
`
`Awaiting production.
`
`(cid:120) Yves Saint Laurent Top Secrets CC Cream Color
`Correcting Primer
`
`(cid:120) Vichy LiftActiv Retinol Anti-Wrinkle Cream
`(cid:120) Vichy Liftactiv Supreme
`(cid:120) Vichy Liftactiv Supreme Serum 10
`(cid:120) Vichy Liftactiv Hyalu Mask
`(cid:120) Vichy LiftActiv Retinol HA Night
`(cid:120) Vichy LiftActiv Retinol HA Eyes
`(cid:120) Vichy Liftactiv Supreme Eyes
`(cid:120) Vichy Liftactiv Supreme Serum 10 Eyes & Lashes
`(cid:120) Vichy Idéalia Night Cream
`(cid:120) Vichy Idéalia Life Serum
`(cid:120) Vichy Idéalia Radiance Serum
`(cid:120) Vichy Idéalia Day Cream
`(cid:120) Vichy Neovadiol Compensating Complex
`(cid:120) Vichy ProEven Daily Dark Spot Serum Corrector
`
`(cid:120) Garnier Miracle Anti-Fatigue Eye Gel Cream
`(cid:120) Garnier Miracle Anti-Fatigue Sleeping Cream
`(cid:120) Giorgio Armani Armani Prima Glow-On Moisturizing
`Cream
`(cid:120) L’Oréal Paris Revitalift Anti-Wrinkle + Firming SPF 30
`Day Lotion
`(cid:120) L’Oréal Paris Revitalift Double Eye Lift
`(cid:120) L’Oréal Paris Revitalift Triple Power SPF 30 Day
`Lotion
`(cid:120) L’Oréal Paris RevitaLift Volume Filler Eye Treatment
`(cid:120) L’Oréal Paris Revitalift Daily Volumizing Moisturizer
`(cid:120) L’Oréal Paris Revitalift Derm Intensives 10% Pure
`Vitamin C
`(cid:120) L’Oréal Paris RevitaLift Triple Power Eye Treatment
`(cid:120) L’Oréal Paris RevitaLift Triple Power Intensive Anti-
`Aging Day Cream Moisturizer
`(cid:120) L’Oréal Paris RevitaLift Triple Power Intensive Skin
`Revitalizer Serum + Moisturizer
`(cid:120) L’Oréal Paris RevitaLift Triple Power Intensive Anti-
`Aging Day Cream Moisturizer Fragrance Free
`(cid:120) L’Oréal Paris RevitaLift Volume Filler Night Cream
`(cid:120) L’Oréal Paris Wrinkle Expert 55+ Anti-Wrinkle Eye
`Treatment
`(cid:120) L’Oréal Paris Youth Code Eye Cream
`
`
`
`5
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 7 of 45 PageID #: 9137
`
`
`
`
`
`
`
`
`Additional
`Marketing
`Materials
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Product Identified by Plaintiffs in D.I. 88 Ex. A
`
`Current Status of Production
`
`(cid:120) L’Oréal Paris Youth Code Texture Perfector Day/Night
`Cream
`(cid:120) L’Oréal Paris Youth Code Texture Perfector Serum
`Concentrate
`(cid:120) L’Oréal Paris Age Perfect Cell Renewal Day SPF 15
`(cid:120) L’Oréal Paris Age Perfect Rosy Tone SPF 30 Sunscreen
`Face Moisturizer
`(cid:120) L’Oréal Paris Visible Lift Radiance Booster
`(cid:120) SkinCeuticals Hyaluronic Acid Intensifier
`(cid:120) SkinCeuticals Metacell Renewal B3
`(cid:120) SkinCeuticals Triple Lipid Restore 242
`
`
`
`6
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 8 of 45 PageID #: 9138
`
`EXHIBIT “(cid:37)”
`
`EXHIBIT “B”
`
`REDACTED IN ITS
`
`(cid:53)(cid:40)(cid:39)(cid:36)(cid:38)(cid:55)(cid:40)(cid:39)(cid:3)(cid:44)(cid:49)(cid:3)(cid:44)(cid:55)(cid:54)(cid:3)
`(cid:40)(cid:49)(cid:55)(cid:44)(cid:53)(cid:40)(cid:55)(cid:60)
`
`ENTIRETY
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 9 of 45 PageID #: 9139
`Case 1:17-cv-00868—CFC-SRF Document 229-1 Filed 06/30/20 Page 9 of 45 PageID #: 9139
`
`EXHIBIT “(cid:38)”
`
`EXHIBIT “C”
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 10 of 45 PageID #:
`9140
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 11 of 45 PageID #:
`9141
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 12 of 45 PageID #:
`9142
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 13 of 45 PageID #:
`9143
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 14 of 45 PageID #:
`9144
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 15 of 45 PageID #:
`9145
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 16 of 45 PageID #:
`9146
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 17 of 45 PageID #:
`9147
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 18 of 45 PageID #:
`9148
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 19 of 45 PageID #:
`9149
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 20 of 45 PageID #:
`9150
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 21 of 45 PageID #:
`9151
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 22 of 45 PageID #:
`9152
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 23 of 45 PageID #:
`9153
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 24 of 45 PageID #:
`9154
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 25 of 45 PageID #:
`9155
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 26 of 45 PageID #:
`9156
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 27 of 45 PageID #:
`9157
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 28 of 45 PageID #:
`9158
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 29 of 45 PageID #:
`9159
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 30 of 45 PageID #:
`9160
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 31 of 45 PageID #:
`9161
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 32 of 45 PageID #:
`9162
`
`EXHIBIT “(cid:39)”
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 33 of 45 PageID #:
`9163
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`UNIVERSITY OF MASSACHUSETTS
`and CARMEL LABORATORIES, LLC,
`
`
`
`
`
`Plaintiffs,
`
`
`
`v.
`
`L’ORÉAL USA, INC.,
`
`
`
`
`
`Defendant.
`
`Case No. 17-cv-868-CFC-SRF
`
`UNIVERSITY OF MASSACHUSETTS AND CARMEL LABORATORIES, LLC’S
`THIRD SET OF REQUESTS FOR PRODUCTION OF DOCUMENTS TO DEFENDANT
`L’OREAL USA, INC.
`Pursuant to Rules 26 and 34 of the Federal Rules of Civil Procedure, Plaintiffs University
`
`of Massachusetts (“UMass”) and Carmel Laboratories, LLC (“Carmel Labs”) hereby request that
`
`Defendant L’Oréal USA, Inc. (“L’Oréal”) produce the following documents and things at the
`
`office of Susman Godfrey L.L.P., 1301 Avenue of the Americas, 32nd Floor, New York, NY
`
`10019, or at such other mutually agreed upon place, within 30 days hereof and in the manner
`
`required by the Federal Rules of Civil Procedure.
`
`DEFINITIONS
`
`1.
`
`The term “UMass” refers to the University of Massachusetts, including any of its past
`
`and present affiliates, operating divisions, campuses, subsidiaries, directors, officers,
`
`agents, employees, representatives, and all persons acting on its behalf.
`
`2.
`
`The term “Carmel Labs” refers to Carmel Laboratories, LLC, including any of its past
`
`and present affiliates, operating divisions, parent corporations, subsidiaries, directors,
`
`officers, agents, employees, representatives, and all persons acting on its behalf.
`
`1
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 34 of 45 PageID #:
`9164
`
`3.
`
`The terms “Defendant,” “You,” “Your,” or “L’Oréal” shall refer to defendant L’Oréal
`
`USA, Inc., and shall include L’Oréal S.A. as well as L’Oréal USA Inc.’s parent,
`
`subsidiaries, affiliates, divisions, successors or assignees, and their respective
`
`officers, directors, employees, consultants, representatives, and agents.
`
`4.
`
`The term “Present Lawsuit” refers to the case styled University of Massachusetts, et
`
`al. v. L’Oréal USA, Inc., Case No. 1:17-cv-00868-CFC-SRF, pending in the United
`
`States District Court for the District of Delaware.
`
`5.
`
`The term “Document” or “Documents” is used in the broadest sense permitted by the
`
`Federal Rules of Civil Procedure and means the original (or any copy when originals
`
`are not available) and any drafts or non-identical copies thereof, whether different
`
`from the original because of interlineations, receipt stamp, notation of copy sent or
`
`received or otherwise, of any email, instant message, voicemail, book, pamphlet,
`
`periodical, letter, report, note, memorandum, record, minutes, calendar or diary entry,
`
`transcript, study, compilation, analysis, tabulation, map, diagram, drawing, plan,
`
`picture, summary, working paper, chart, paper, graph index, data sheet, data
`
`processing card, computer printout, summary of a computer printout, tape, contract,
`
`agreement, lease, ledger, journal, balance sheet, account, invoice, purchase order,
`
`receipt, billing record, financial data, financial statement, file, diary, film, trip tickets,
`
`telex, teletype or other messages, telegram, expense vouchers, instructions, bulletins
`
`or any other writing or recording of information, as well as all tape recordings,
`
`computer tapes, discs and other electronic or mechanical recordings, however
`
`produced, maintained or reproduced, including information stored in or generated by
`
`a computer whether or not ever printed out or displayed, within the possession,
`
`2
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 35 of 45 PageID #:
`9165
`
`custody or control of Defendant or any of its officers, directors, employees, attorneys,
`
`or other agents and/or representatives.
`
`6.
`
`The term “Person” means natural person, corporation, firm, company, sole
`
`proprietorship, partnership, joint venture, association, institute, or other business,
`
`legal or governmental entity or association, including any directors, officers,
`
`employees, agents or representatives thereof.
`
`7.
`
`8.
`
`The term “Agreement” means a contract, agreement, arrangement, or understanding,
`
`formal or informal, oral or written, between two or more persons.
`
`The term “Communication” refers to any transfer of information, oral or written, be it
`
`in the form of facts, ideas, inquiries, opinions or otherwise, by any means, at any time
`
`or place, under any circumstances, and is not limited to transfers between persons, but
`
`includes other transfers, such as records and memoranda to the file.
`
`9.
`
`The phrase “Relating To” means discussing, describing, referring to, pertaining to,
`
`containing, analyzing, studying, reporting on, commenting on, evidencing,
`
`constituting, setting forth, considering, recommending, concerning, or pertaining to,
`
`in whole or in part.
`
`10.
`
`The terms “Asserted Patents” and “Patents-in-Suit” shall mean United States Patents
`
`No. 6,423,327 and 6,645,513.
`
`The term “’327 Patent” refers to U.S. Patent No. 6,423,327.
`
`The term “’513 Patent” refers to U.S. Patent No. 6,645,513.
`
`The term “Prior Art” means any evidence qualifying as prior art to the Patents-in-Suit
`
`11.
`
`12.
`
`13.
`
`under 35 U.S.C. § 102 and/or 35 U.S.C. § 103.
`
`14.
`
`The terms “all” and “each” shall be construed as “and,” “each,” and “and/or.”
`
`3
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 36 of 45 PageID #:
`9166
`
`15.
`
`The term “any” should be understood in either its most or least inclusive sense as will
`
`bring within the scope of the topic all responses that might otherwise be construed to
`
`be out of its scope.
`
`16.
`
`17.
`
`The term “including” shall mean including but not limited to.
`
`The terms “relate,” “relating,” or “related” mean in any way, directly or indirectly, in
`
`whole or part, relating to, concerning, referring to, discussing, mentioning, regarding,
`
`pertaining to, describing, reflecting, containing, analyzing, studying, reporting on,
`
`commenting on, evidencing, constituting, setting forth, considering, recommending,
`
`modifying, amending, confirming, endorsing, representing, supporting, qualifying,
`
`terminating, revoking, refuting, undermining, canceling, contradicting or negating.
`
`18.
`
`The terms “and” and “or” shall be construed disjunctively or conjunctively as
`
`necessary to bring within the scope of these topics all information which might
`
`otherwise be construed to be outside their scope.
`
`19.
`
`References to the singular shall include the plural, and references to the plural shall
`
`include the singular as may be appropriate to construe the individual document
`
`requests in their broadest form.
`
`20.
`
`The masculine form of a noun or pronoun shall be considered to include within its
`
`meaning the feminine form of the noun or pronoun, and vice versa as may be
`
`appropriate to make the individual document requests inclusive rather than exclusive.
`
`21.
`
`The term “Accused Products” refers to the products listed in Exhibit A to Plaintiffs’
`
`Disclosure of Asserted Claims and Initial Infringement Contentions, served on
`
`October 10, 2019, subject to any subsequent supplement or amendment.
`
`4
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 37 of 45 PageID #:
`9167
`
`INSTRUCTIONS
`
`1.
`
`Responsive documents shall be produced as they have been kept in the usual course
`
`of business and shall not be shuffled or otherwise rearranged. Alternatively, you may
`
`produce responsive documents organized and labeled to correspond to the enumerated
`
`requests of this demand. If any portion of any document is responsive to any request,
`
`then the entire document must be produced. Documents that are found stapled,
`
`clipped, or otherwise fastened together shall be produced in such form. If there is no
`
`document responsive to any particular category, you shall so state in writing.
`
`2.
`
`If any portion of a document is responsive to an individual document request, then the
`
`entire document shall be produced. If the document contains privileged material,
`
`produce the entire document with the privileged material redacted, noting the
`
`redactions on the face of the document.
`
`3.
`
`If information stored in, or accessible through, computer or other data retrieval
`
`systems is produced, it must be accompanied with instructions and all other materials
`
`4.
`
`5.
`
`necessary to use or interpret such data.
`
`All documents which cannot be legibly copied should be produced in their original
`
`form.
`
`Each individual document request set forth herein shall be construed independently
`
`and not with reference to any other request for purposes of limitation unless a
`
`particular request so specifies.
`
`6.
`
`Where specific documents are listed as part of a general category of documents, then
`
`such listed documents as well as all other documents falling within such general
`
`category shall be produced. If any responsive document is withheld under a claim of
`
`5
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 38 of 45 PageID #:
`9168
`
`privilege, You shall furnish a list specifying each such document and setting forth the
`
`following information: (i) the date of the document; (ii) the number of pages of the
`
`document; (iii) the name and last known address of each person who prepared or
`
`participated in the preparation of the document; (iv) the name and last known address
`
`of each addressee or other person to whom the document, or any part thereof, was
`
`sent or to whom the document or its contents, or any part thereof, was disclosed; (v) a
`
`summary of the general subject matter of the document (and such other information
`
`as is necessary to identify the document such as whether the document is a letter or
`
`memorandum); (vi) a statement of the basis upon which the asserted privilege is
`
`claimed; and (vii) the individual document request herein to which the document is
`
`responsive. If no documents are withheld under a claim of privilege, so state. Any
`
`document or part of a document withheld under a claim of privilege must be
`
`preserved.
`
`7.
`
`If any document responsive to this request once existed but has been destroyed or
`
`discarded, or is otherwise not capable of being produced, You shall furnish a list
`
`specifying each such document and setting forth the following information: (i) the
`
`date of the document; (ii) a description of the subject matter of the document; (iii) the
`
`name and last known address of each person who prepared or participated in the
`
`preparation of the document; (iv) the name and last known address of each addressee
`
`or other person to whom the document, or any part thereof, was sent or to whom the
`
`document or its contents, or any part thereof, was disclosed; (v) the name and last
`
`known address of any person not covered by items (iii) and (iv) who had possession,
`
`custody or control of the document or a copy thereof; (vi) the date on which the
`
`6
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 39 of 45 PageID #:
`9169
`
`document was destroyed or discarded and a statement of the reasons why the
`
`document was destroyed or discarded or why such document is not capable of being
`
`produced; and (vii) the individual document request herein to which the document is
`
`responsive.
`
`8.
`
`9.
`
`Unless otherwise specified, the documents requested herein are documents prepared,
`
`written, sent, dated, received, or in effect at any time on or after October 26, 1998.
`
`This request for documents shall be deemed continuing in nature so as to require
`
`prompt supplemental responses in accordance with Rule 26(e) of the Federal Rules of
`
`Civil Procedure in the event You become aware of, or acquire within Your
`
`possession, custody, or control, additional responsive documents at any time
`
`hereafter.
`
`REQUEST FOR PRODUCTION
`
`REQUEST FOR PRODUCTION NO. 38: Documents sufficient to show all sales, cost, and
`
`revenue information, by number of units sold and by dollars of revenue, for the Accused
`
`Products, broken down by quarter, including all documents sufficient to explain any acronyms or
`
`terminology employed by Your accounting system.
`
`REQUEST FOR PRODUCTION NO. 39: Documents sufficient to show Your gross,
`
`contribution, and operating profits and gross, contribution, and operating profit margins from
`
`sales of the Accused Products.
`
`REQUEST FOR PRODUCTION NO. 40: All documents that refer or relate to market surveys,
`
`market analyses, market forecasts, and/or sales forecasts, including but not limited to documents
`
`that relate to Your competitors in these markets, for the Accused Products. This Request includes
`
`reports by external analysts or consultancies.
`
`7
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 40 of 45 PageID #:
`9170
`
`REQUEST FOR PRODUCTION NO. 41: All documents relating to market share, whether
`
`Yours or of a competitor, of total products sold and total revenue in the markets for the Accused
`
`Products.
`
`REQUEST FOR PRODUCTION NO. 42: All documents that refer or relate to Your strategic
`
`plans, business plans, business strategies, licensing plans, licensing proposals, licensing
`
`forecasts, prospectuses, market surveys, marketing strategies, market analyses, and/or marketing
`
`forecasts of customer demand for the Accused Products.
`
`REQUEST FOR PRODUCTION NO. 43: All licenses You hold relating to U.S. Patent Nos.
`
`9,018,177; 9,023,826; 9,072,919; and 9,107,853; and all documents You received from L’Oréal
`
`S.A. related to those patents, including but not limited to file histories and documents related to
`
`any post-grant review or proceeding.
`
`REQUEST FOR PRODUCTION NO. 44: All documents that refer or relate to customer or
`
`clinical surveys or studies involving the Accused Products.
`
`REQUEST FOR PRODUCTION NO. 45: All documents, including consumer surveys and
`
`consumer questions submitted to You, discussing or showing how customers use or apply the
`
`Accused Products.
`
`REQUEST FOR PRODUCTION NO. 46: All documents, including product packaging,
`
`websites, and videos, showing or instructing customers how to use the Accused Products.
`
`REQUEST FOR PRODUCTION NO. 47: All documents relating to any price lists for any
`
`Accused Product.
`
`REQUEST FOR PRODUCTION NO. 48: All documents that constitute, evidence, or relate to
`
`Your accounting practices pertaining to the Accused Products, including but not limited to Your
`
`methods of accounting for revenues, costs and profits, methods of depreciation, allocation of
`
`8
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 41 of 45 PageID #:
`9171
`
`expenses, inventory measurements, profit allocation, and losses and assignments of debt.
`
`REQUEST FOR PRODUCTION NO. 49: All expert reports and expert deposition transcripts
`
`produced in the matter Liqwd, Inc. v. L’Oreal USA, Inc., No. 17-14 (JFB) (D. Del.).
`
`REQUEST FOR PRODUCTION NO. 50: All documents that refer or relate to testing of any
`
`Accused Product.
`
`REQUEST FOR PRODUCTION NO. 51: All documents that refer or relate to promotional or
`
`marketing materials for any Accused Product.
`
`REQUEST FOR PRODUCTION NO. 52: All documents that tend to prove or disprove
`
`whether any Accused Product, or any ingredient of any Accused Product, causes dermal cell
`
`proliferation.
`
`REQUEST FOR PRODUCTION NO. 53: All documents relating to Your decision to include
`
`adenosine in certain skincare products
`
` as described in Your supplemental
`
`objections and response to Interrogatory No. 6.
`
`REQUEST FOR PRODUCTION NO. 54: All documents that tend to prove or disprove that
`
`each Accused Product contains at least one skin conditioning agent.
`
`REQUEST FOR PRODUCTION NO. 55: Documents sufficient to show all skin conditioning
`
`agents of which You are aware.
`
`REQUEST FOR PRODUCTION NO. 56: All documents that tend to prove or disprove that
`
`each Accused Product contains at least one transdermal agent and/or penetration enhancer.
`
`REQUEST FOR PRODUCTION NO. 57: Documents sufficient to show all transdermal agents
`
`and/or penetration enhancers of which You are aware.
`
`9
`
`

`

`Case 1:17-cv-00868-CFC-SRF Document 229-1 Filed 06/30/20 Page 42 of 45 PageID #:
`9172
`
`REQUEST FOR PRODUCTION NO. 58: All documents that tend to prove or disprove that
`
`each Accused Product is intended for use by human mammals.
`
`REQUEST FOR PRODUCTION NO. 59: All documents that tend to prove or disprove that
`
`each Accused Product reduces one or more of wrinkling, roughness, dryness, or laxity when
`
`topically applied to the skin.
`
`REQUEST FOR PRODUCTION NO. 60: All documents that tend to prove or disprove that
`
`each Accused Product causes adenosine to reach the dermal layer in a concentration of
`
`approximately 10-3 to 10-7.
`
`REQUEST FOR PRODUCTION NO. 61: All documents that tend to prove or disprove that
`
`each Accused Product is intended to be applied to unbroken skin.
`
`REQUEST FOR PRODUCTION NO. 62: All documents that tend to prove or disprove that
`
`You direct customers to apply the Accused Products topically to their skin.
`
`REQUEST FOR PRODUCTION NO. 63: Documents sufficient to identify any ingredient,
`
`formula, or product codes in any documents produced in this litigation, including but not limited
`
`to the “RM” codes used in Your Research & Innovation documents.
`
`REQUEST FOR PRODUCTION NO. 64: Documents sufficient to identify when the following
`
`brands were formed, acquired, or sold by